Published in final edited form as:

Placenta. 2017 December ; 60: 119–129. doi:10.1016/j.placenta.2017.06.005.

Emerging Role for Dysregulated Decidualization in the Genesis of Preeclampsia

Kirk P. Conrad^a, Maria Belen Rabaglini^b, and Emiel D. Post Uiterweer^c

^aDepartments of Physiology and Functional Genomics, and of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, FL 32610 ^bDepartment of Animal Reproduction, Universidad Nacional de Rio Cuarto, Rio Cuarto, Cordoba, Argentina ^cDepartment of Obstetrics and Laboratory of Neuroimmunology and Developmental Origins of Disease, University Medical Center Utrecht, Utrecht, The Netherlands

Abstract

In normal human placentation, uterine invasion by trophoblast cells and subsequent spiral artery remodeling depend on cooperation among fetal trophoblasts and maternal decidual, myometrial, immune and vascular cells in the uterine wall. Therefore, aberrant function of anyone or several of these cell-types could theoretically impair placentation leading to the development of preeclampsia. Because trophoblast invasion and spiral artery remodeling occur during the first half of pregnancy, the molecular pathology of fetal placental and maternal decidual tissues following delivery may not be informative about the genesis of impaired placentation, which transpired months earlier. Therefore, in this review, we focus on the emerging *prospective* evidence supporting the concept that deficient or defective endometrial maturation in the late secretory phase and during early pregnancy, i.e., pre-decidualization and decidualization, respectively, may contribute to the genesis of preeclampsia. The first prospectively-acquired data directly supporting this concept were unexpectedly revealed in transcriptomic analyses of chorionic villous samples (CVS) obtained during the first trimester of women who developed preeclampsia 5 months later. Additional supportive evidence arose from investigations of Natural Killer cells in first trimester decidua from elective terminations of women with high resistance uterine artery indices, a surrogate for deficient trophoblast invasion. Last, circulating insulin growth factor binding protein-1, which is secreted by decidual stromal cells was decreased during early pregnancy in women who developed preeclampsia. We conclude this review by making recommendations for further prospectively-designed studies to corroborate the concept of endometrial antecedents of preeclampsia. These studies could also enable identification of women at increased risk for developing preeclampsia, unveil the molecular mechanisms of deficient or defective

Kirk P. Conrad MD, Departments of Physiology and Functional Genomics, University of Florida College of Medicine, 1600 SW Archer Road, PO Box 100274 M552, Gainesville, FL 32610, USA, ph 352-392-2798, kpconrad@ufl.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Portions of this work were presented at the 2016 Global Pregnancy Collaboration (CoLab) Conference in Oxford, England.

(pre)decidualization, and lead to preventative strategies designed to improve (pre)decidualization, thereby reducing risk for preeclampsia development.

Keywords

placenta; trophoblast; endometrium; decidua; immune cells; maternal-fetal interface

Introduction

In healthy human pregnancies, placentation is associated with invasion of the placental bed by two populations of extravillous trophoblast cells— “endovascular” and “interstitial” trophoblasts, which invade the uterine spiral arteries and interstitium, respectively. The placental bed comprises the gestational endometrium or decidua, and inner one-third of the myometrium. Uterine trophoblast invasion occurs during the first half of gestation resulting in apoptosis of endothelial and smooth muscle cells, as well as degradation of extracellular matrix in uterine spiral arteries with deposition of fibrinoid material and incorporation of trophoblasts within the vascular walls. Through these processes, the spiral arteries transform from narrow caliber, high resistance to large caliber, low resistance vessels resulting in increased delivery of blood flow of reduced velocity to the intervillous space beginning at approximately 8 gestational weeks, thus providing oxygen and nutrients to the growing placenta and fetus [1–4]. Ultimately, the successful completion of this remarkable physiological chain of events hinges on the invasive potential of extravillous trophoblasts (“seed”), receptivity of the decidua including the spiral arteries (“soil”) for these invading fetal cells, and their seamless interactions.

The genesis of preeclampsia is widely believed to reside in the placental bed during early pregnancy. Namely, preeclampsia is associated with deficient uterine invasion by endovascular trophoblasts and incomplete remodeling of spiral arteries in the inner one-third of the myometrium [3–5]. The decidual spiral arteries may be similarly affected, but to a more variable extent [5–8], while interstitial trophoblast invasion has been reported to be impaired by some investigators and normal by others [5, 8, 9]. Ultimately, however, structural deficiency of the spiral arteries precludes the establishment of normal blood flow patterns in the intervillous space resulting in placental damage, ischemia, and ischemia-reperfusion injury [1, 2, 10]. Recently, this pathological chain of events has been ascribed to early- (<34 gestational weeks), but not late-onset preeclampsia, the latter being attributed to overcrowding of villous as the placenta reaches its full growth potential, thereby impeding intervillous blood flow [11]. Although deficient placentation and villous overcrowding may predominate in early- and late-onset preeclampsia, respectively, there may not be a strict, gestational age cutoff separating these two pathogenic entities. For example, in a woman who develops preeclampsia manifestations at 35 or 36 gestational weeks, some degree of spiral artery pathology may be one factor underlying her disease. Moreover, the gestational age at which disease manifestations emerge may also be determined by interaction of the deleterious factors released from the damaged placenta (e.g., anti-angiogenic growth factors, proinflammatory cytokines and syncytiotrophoblast microparticles) with maternal constitutional factors [12, 13]. In this regard, it is not inconceivable that some women may

have considerable placental pathology stemming from impaired placentation as described above, but are relatively resistant to the damaging effects of the circulating placental factors, thus not developing disease until later in gestation, when the placental factors ultimately become overwhelming. In contrast, other women may be relatively vulnerable due to comorbidities like obesity, metabolic syndrome or chronic hypertension, thereby developing disease earlier in pregnancy with little placental pathology. The placental and maternal constitutional etiologies of preeclampsia ultimately converge on the maternal endothelium to produce disease manifestations [13–16]. Although not mutually exclusive, other maternal factors could also contribute to the development of preeclampsia that are not necessarily related to endothelial function [17, 18]. Finally, it should be noted that deficient placentation is not unique to the pathogenesis of preeclampsia, but also underlies many cases of normotensive intrauterine growth restriction, preterm labor, late sporadic miscarriage and abruptio placentae [19, 20].

Extravillous Trophoblast Gene Expression and Function After Onset of Clinical Disease

The extravillous trophoblast is a logical target for scientific inquiry, because uterine invasion is suboptimal in preeclampsia (*vide supra*), and the proposed paternal genetic contribution to the disease could be expressed through this fetal cell-type [21]. In pioneering work, Fisher and colleagues extensively phenotyped endovascular trophoblasts in normal and preeclamptic pregnancies *in situ* on placental bed biopsies [1, 22, 23], and investigated cell invasion *in vitro* [24]. These investigators reported that, as the endovascular trophoblasts invade the uterus, they normally undergo an epithelial-to-endothelial transition and increase expression of angiogenic molecules—processes which are compromised in preeclampsia [22]. (It should be pointed out that not all subscribe to the concept of endovascular trophoblast epithelial-to-endothelial transition [9]). The invasive potential of villous cytotrophoblasts isolated from preeclamptic placentas and studied *in vitro* was also found to be restricted [25], generally consistent with the finding of deficient invasion *in situ* [3–9, 26]. Moreover, the molecular and cellular defects of extravillous trophoblasts identified both *in situ* and *in vitro* were largely consistent [22, 25, 27].

An important caveat is that these studies are *retrospective*, insofar as extravillous trophoblast gene expression, phenotype and function were investigated after appearance of disease manifestations. Conceivably, the observed defects could have arisen in response to the myriad of factors emanating from the syncytiotrophoblast during disease that may not be only injurious to the maternal endothelium, but also to extravillous trophoblasts. Alternatively, they could have occurred as a direct consequence of the ischemia and ischemia-reperfusion injury that afflicts the preeclamptic placenta secondary to deficient placentation. In the same vein, it is unclear whether the extravillous trophoblast gene and phenotypic expression, as well as decreased invasive capacity observed after disease onset, are irreversible or not. In one study, when villous cytotrophoblasts were isolated from preeclamptic women and investigated in cell culture, defective gene and phenotypic expression, and decreased invasive capacity persisted [25]. In contrast, the expression of many genes reverted to normal levels after 48 hours in culture in another study, although

invasive potential was apparently not assessed [27]. If gene and phenotypic expression, and reduced invasive capacity are reversible in culture, these findings could implicate the uterine milieu as an inciting factor, i.e., the villous environment from which these trophoblast cells were isolated, perhaps modified by factors emanating from the decidua into the spiral arteries, which then travel to the intervillous space in the blood. Nevertheless, even if the observed abnormalities reverted to normal in culture, it is impossible to determine whether the injurious agents in the uterine milieu after disease onset would be the same as those in the uterine milieu months before disease onset, when the extravillous trophoblasts were invading.

In summary, elucidation of extravillous trophoblast gene and phenotypic expression in late pregnancy may bear little or no relation to early pregnancy, when these cells invade and remodel spiral arteries of the uterus—the critical time when extravillous trophoblasts presumably derail in women who will develop preeclampsia. Clearly, the abnormal gene expression and cell phenotype reported in extravillous trophoblasts during disease could impair their function at that late stage [27], and contribute to disease symptoms. But, it can be argued that, in order to unveil the initial molecular derangements underlying deficient trophoblast invasion and spiral artery remodeling in preeclampsia, *prospective* investigations of trophoblasts and decidua (*vide infra*) obtained either before or at least coincident with the unfolding of these physiological events in early pregnancy is required. Indeed, gene expression in trophoblasts and decidua may be completely different in early pregnancy bearing little or no relation to delivered tissues as recently reported [28] (and see below).

Decidua

Another relevant tissue to consider is the decidua into which extravillous trophoblasts invade. However, much less attention has been given to decidua than trophoblasts. The hypothesis that deficient or defective endometrial maturation or decidualization could contribute to the genesis of preeclampsia is a logical deduction based on the intimate proximity of extravillous trophoblasts, decidual and immune cells, and spiral arteries within the placental bed [29, 30]. Further, the concept fits with the maternal inheritance pattern of preeclampsia, which could predispose to deficient or defective (pre)decidualization as an etiological factor in the disease [21].

Briefly, uterine luminal and glandular epithelial, as well as stromal cells undergo distinct changes in morphology, gene expression and function beginning in the secretory phase (“pre-decidualization”) and continuing after implantation (“decidualization”) [31]. Spiral arteries are likewise modified by decidualization preceding invasion of extravillous trophoblasts [26, 32]. Decidual changes in uterine glandular epithelium are also prerequisite to histiotrophic nutrition of the placenta and fetus before the start of intervillous blood flow and hemotrophic nutrition at ~10 gestational weeks [33]. In women, part and parcel of (pre)decidualization is increased number of decidual Natural Killer (dNK) cells of an immunomodulatory phenotype with reduced capacity for cytotoxicity [34]. Importantly, dNK cells likely play key roles in promoting trophoblast invasion and spiral artery remodeling [34–36]. As well, increased decidual and myometrial macrophage number of an alternatively-activated (“M2”) phenotype accumulate [37], and T regulatory cells are also

believed to exert an important role in uterine immune tolerance to the fetal/placental semi-allograft [38]. Fundamentally, decidualization is preparation of the “soil” for the “seed” (embryo implantation and placentation). Thus, it is reasonable to propose that abnormalities of decidualization beginning before and continuing during early pregnancy could compromise endovascular trophoblast invasion and spiral artery remodeling. For example, deficient or defective endometrial maturation could adversely impact extravillous trophoblasts as they initially transit the decidua, thereby curtailing invasion of the underlying myometrium. Alternatively, the inner one-third of the myometrium may also undergo a kind of “decidualization”, which is compromised in women who develop preeclampsia, thereby precluding deep extravillous trophoblast invasion [29]. NK cells confined to the decidua may play a major role in orchestrating extravillous trophoblast invasion and spiral artery remodeling in the decidua (*vide supra*), while uterine macrophages also present in the inner one-third of the myometrium, could conceivably play a similar role in this region of the placental bed [37]. With impairment of decidualization, the optimal number and phenotype of these immune cells residing in the decidua and myometrium would be compromised.

Decidual Gene Expression and Function After Onset of Clinical Manifestations

Several retrospective investigations of decidual basal plate in delivered placentas from women with preeclampsia have been reported. These studies demonstrated altered pro-inflammatory cytokine expression [39–43], as well as abnormal T regulatory [44, 45] and macrophage number and phenotype [37, 46, 47] in the decidua of affected women. However, as advanced above, the argument can be made that the retrospective nature of these investigations precludes identifying these pathologic features as either cause or consequence of preeclampsia. For example, dramatically elevated levels of circulating deleterious factors emanating from the syncytiotrophoblast during pregnancy in women with preeclampsia such as sFlt1, sEng, TNF α , IL-6 and syncytiotrophoblast microparticles may not only be injurious to the endothelium (including of spiral arteries), but also to other cell-types such as decidual stromal, epithelial, and uterine immune cells. Although these decidual abnormalities reported in the basal plate of delivered placentas could impact extravillous trophoblast function at this late stage and contribute to disease symptoms, they may not be manifested before and/or during early pregnancy coincident with the critical period of trophoblast invasion and spiral artery remodeling [28] (see **Bioinformatic Comparison of Transcriptomics in Chorionic Villous Samples vs Delivered Placental Tissues in Preeclampsia**, below).

Decidual Gene Expression and Function Before Onset of Clinical Manifestations

The pioneering work of Cartwright and colleagues partly addresses the concern about whether decidual pathology may be cause or consequence of preeclampsia [35]. They harvested NK cells from decidua of first trimester placentas obtained after elective termination. Immediately prior to elective termination, Doppler ultrasound was performed to evaluate the uterine artery resistance index. High resistance uterine artery indices were

previously found to correlate with decreased endovascular trophoblast invasion of decidual spiral arteries [48]. This finding is consistent with the correlation between high uterine artery resistance index and decreased endovascular trophoblast invasion of decidual and myometrial spiral arteries in women with preeclampsia [49]. In the first trimester decidual tissues from pregnancies with high uterine artery index, Cartwright et al. identified perturbed gene expression and aberrant dNK cell phenotype, as well as impaired regulation of trophoblast function by dNK cells *in vitro* [35]. Although supportive of the concept of dysregulated decidua and dNK cells as one potential etiology of preeclampsia, these prospective data are not conclusive, because elevated resistance uterine artery indices are not highly predictive of preeclampsia [50, 51].

Another unexpected line of prospective evidence supports the concept of endometrial antecedents of preeclampsia. Scattered over a period of 12 years from 1996 to 2008, six reports emerged in the literature all showing reduced levels of a decidual secretory protein, insulin growth factor binding protein-1 (IGFBP1), in the circulation of women during the first or second trimester who later developed preeclampsia [52–57] (Table 1 and Fig. 1). One interpretation of these findings is that deficient trophoblast invasion reduces the deportation of decidual IGFBP1 into the maternal circulation [52]. However, another explanation is that reduced circulating IGFBP1 reflects a primary deficiency or defect in endometrial cell maturation, and hence, IGFBP1 production [53].

Further prospective evidence supporting the concept of endometrial antecedents of preeclampsia is provided by investigations we conducted on chorionic villous samples (CVS) obtained from women who developed preeclampsia [28, 58]. Previously, we conducted a number of investigations into the molecular pathology of delivered placentas from women with preeclampsia with a focus on hypoxia inducible transcription factors and downstream genes, e.g., [59–61]. However, we did not know whether the upregulation of hypoxia-inducible transcription factors and downstream genes in preeclamptic placentas was a distal or proximal event in the disease, and the only approach that we knew to address this question was to begin collection of surplus CVS. Approximately 130 specimens of 10–12 gestational weeks were snap frozen within 5–10 minutes of uterine abstraction from 2001–2005. Four of the women (~3%) developed severe preeclampsia, and we matched them with 8 women who experienced normal pregnancies. The tissues were then subjected to transcriptomic analysis. Surprisingly, the hypothesis-driven component of the project was not supported, i.e., there was no evidence for upregulation of hypoxia (or oxidative stress) regulated genes [58]. Rather, there emerged a strong signature of dysregulation of decidual gene expression, e.g., downregulation of IGFBP1, glycodelin, prolactin and IL-15 [28, 58]. A synopsis of the rationale, findings and major conclusions of this study follow.

We employed systems biology approaches [28, 62] to test the hypothesis that aberrant decidualization both before and during early pregnancy precedes preeclampsia [58]. Specifically we hypothesized that preeclampsia is antedated by dysregulated maturation of the endometrium leading to compromised local immune cell number and phenotype, i.e., sub-optimal (pre)decidualization. In turn, these endometrial defects compromise extravillous trophoblast invasion, spiral artery remodeling and placentation [30, 63–66]. Because endometrial maturation during the secretory phase and early pregnancy is a biological

continuum, both impaired pre-decidualization and decidualization are likely. We reasoned that, if the genes regulated in the endometrium and in dNK cells during the normal biological processes of (pre)decidualization [67–71] were changed in the opposite direction in CVS from women who developed preeclampsia (PE-CVS) relative to normal pregnancy (NP-CVS) [58], then this prospective evidence would provide the crucial linkage needed to underpin the concept of “endometrial antecedents of preeclampsia”.

We cast a wide net and included differentially expressed genes (DEG) determined by fold-change, t-test ($p < 0.05$) and J5 test for subsequent bioinformatics [28, 58]. There were a total of 396 DEG between PE- and NP-CVS of which 195 were down- and 201 up-regulated in PE-relative to NP-CVS [28]. A large number, 154 or 40%, overlapped with DEG associated with various stages of normal endometrial maturation before and after implantation as identified in other microarray data sets in the public domain ($p = 4.7 \times 10^{-14}$). One-hundred and sixteen of the 154 DEG or 75% overlapped with DEG associated with normal decidualization in the *absence* of extravillous trophoblasts, i.e., late secretory endometrium and endometrium from tubal ectopic pregnancy ($p = 4.2 \times 10^{-9}$). Finally, 112 of these 154 DEG or 73% were changed in the opposite direction in microarray data sets related to normal endometrial maturation ($p = 0.01$). For example, 16 DEG *up-regulated* in decidual relative to peripheral NK cells were *down-regulated* in CVS from women who developed PE vs NP ($P < 0.0001$) consistent with decidual NK cell dysregulation. Overall, these results suggest that insufficient or defective maturation of endometrial and dNK cells or reduced numbers during the secretory phase and early pregnancy preceded development of preeclampsia [28].

Figure 2 depicts $\log_2$ mean expression values for the DEG down-regulated in PE-CVS (relative to NP-CVS) that were: **(A)** uniquely upregulated in late secretory relative to proliferative endometrium (20 DEG), **(B)** uniquely upregulated in histologically-classified intermediate and confluent decidualized endometrium from early pregnancy (relative to non-decidualized endometrium; 13 DEG), and **(C)** upregulated in late secretory endometrium, intermediate and confluent decidualized endometrium (16 DEG). For the 20 DEG identified as uniquely up-regulated in late secretory endometrium (i.e., their average expression did not further increase with decidualization early in pregnancy) and down-regulated in CVS-PE, the average gene expression was significantly less in PE-CVS than in NP-CVS by ~2-fold (Fig. 2A). These findings suggest that impairment of endometrial maturation in the women who developed PE began before pregnancy in the secretory phase. The 13 DEG down-regulated in CVS-PE and up-regulated in intermediate and confluent decidualized endometrium from early pregnancy, slightly increased in late secretory endometrium, but mostly rose during decidualization in early pregnancy (Fig. 2B). Average gene expression for these 13 DEG was markedly less in PE-CVS than NP-CVS by ~3-fold. These results suggest that, in addition to a defect in pre-decidualization as described, there was also impairment of decidualization after implantation in the women who developed preeclampsia. Finally, the 16 DEG down-regulated in CVS-PE and up-regulated in late secretory endometrium, intermediate and confluent decidualized endometrium increased expression beginning in the mid-secretory endometrium and progressively rose thereafter. In this case, average gene expression of the 16 DEG was ~7-fold less in PE-CVS compared to NP-CVS

(Fig. 2C and D), indicating again that pre-decidualization and decidualization were compromised in the women who developed preeclampsia.

Decidual macrophages may also have been dysregulated during early pregnancy in the women who developed preeclampsia. Gustafsson and colleagues investigated gene expression in CD14⁺ decidual macrophages isolated from first trimester placenta acquired through elective terminations and the CD14⁺ macrophages isolated from the corresponding peripheral blood [72]. We reanalyzed the DNA microarray data available in the Gene Expression Omnibus (GEO) database (accession number GSE10612) using fold-change > 2.0 and $p < 0.05$ as criteria for selecting DEG. There was a total of 1078 DEG between decidual and peripheral blood CD14⁺ macrophages, of which 54 overlapped with the 396 DEG in PE-CVS ($p=7.0 \times 10^{-20}$). Of these 54 overlapping DEG, 37 or 69% changed in the opposite direction. Specifically, there were 12 DEG upregulated in PE-CVS that were downregulated in CD14⁺ decidual macrophages ($p=1.1 \times 10^{-6}$) and 25 DEG downregulated in PE-CVS and upregulated in CD14⁺ decidual macrophages ($p=9.5 \times 10^{-13}$). Thus, in addition to NK cells (*vide supra*), taking a similar bioinformatics approach reveals the possibility that macrophages may also have been abnormal in the decidua of women who later developed preeclampsia.

Bioinformatic Comparison of Transcriptomics in Chorionic Villous Samples vs Delivered Placental Tissues in Preeclampsia

To reinforce the concept that the molecular pathology of delivered placental tissues—villous, decidua or isolated villous cytotrophoblasts—apparently bear little resemblance to the placenta in early pregnancy (CVS) from women who developed severe preeclampsia as discussed above, we performed further bioinformatical analyses (Table 2A and B). The results demonstrate little or no overlap of DEG changing in the same direction between CVS and delivered placental tissues—chorionic villous, isolated villous cytotrophoblasts or decidual basal plate [27, 73–78]

Potential Mechanisms of Impaired Decidualization in Preeclampsia

Figure 3 summarizes our current thinking about the concept of endometrial antecedents of preeclampsia and potential etiological factors. Several diseases have been reported to both impair decidualization and predispose to preeclampsia including polycystic ovarian syndrome [79–84], obesity [79, 80, 85, 86], diabetes mellitus [87–89], and endometriosis [90–92]. These comorbidities may exert their disruptive action on the endometrium through anomalous inflammation, exaggerated production of androgens, insulin, and homocysteine, as well as pathological epigenetic modifications [79, 91, 93–96]. Indeed, epigenetic dysregulation is another likely instigating factor, insofar as much of the normal biological process of decidualization is epigenetically regulated [97–103]. Genetic factors include certain pairings of highly polymorphic KIR receptors on dNK cells with HLA-C ligands on extravillous trophoblasts that increase the risk for preeclampsia [34]. Seminal plasma has been reported to modulate immune cell number and function in the uterus. In particular, seminal fluid was shown to stimulate CCL19 expression by glandular and luminal epithelial cells that, in turn, recruited T regulatory cells into the uterus via the CCR7 receptor prior to

embryo implantation in mice [104]. Thus, it is not inconceivable that lack of timely or sufficient exposure to seminal plasma may predispose to preeclampsia [105]. We further postulate that the increased risk of preeclampsia in donor egg recipient [106] and frozen embryo transfer [107–109] pregnancies may in part stem from lack of fine tuning of decidualization by corpus luteal products like relaxin (and perhaps other, as of yet, undiscovered corpus luteal factors), which is missing, if embryo transfer occurs in the absence of a corpus luteum. Finally, with the revelation of intimate host-microbial interactions in the gut and other organs [110–112], the existence of an endometrial microbiome is a distinct possibility, which has recently gained support [113–115]. Whether a normal endometrial microbiome contributes to the biological process of (pre)decidualization possibly through influencing epigenetic events [116], and whether an abnormal microbiome impairs (pre)decidualization, thus predisposing to preeclampsia, are obvious questions that need to be addressed in future investigations.

Future Investigations

Although fraught with formidable logistical challenges and inherent shortcomings, additional prospective studies are needed to reinforce the concept of endometrial antecedents of preeclampsia. To this end, further “omics” analyses of surplus CVS are needed in larger cohorts of women who develop preeclampsia. The several institutions around the world still performing CVS in sufficient numbers could collaborate and coordinate collection of surplus CVS to be processed for RNA (and other analyses) immediately after uterine extraction. Clearly, the logistical challenges include the recent emergence of non-invasive prenatal diagnosis, which is dramatically reducing CVS procedures, the requirement for rapid processing of the surplus CVS tissue to preserve high quality RNA, and the need for obtaining obstetrical outcomes. Nevertheless, to our knowledge, there is no other way to obtain decidua from early pregnancy and the obstetrical outcome, which are both essential for testing the endometrial antecedents of preeclampsia.

Because our transcriptomic and bioinformatics analyses of surplus CVS suggested deficiency of both pre-decidualization and decidualization in women who developed preeclampsia [28, 58] (Fig. 2), we have been obtaining endometrial biopsies during the late secretory phase of women who experienced severe preeclampsia in the previous pregnancy. The overall goal is to determine whether there is dysregulation of pre-decidualization in a non-conceptive cycle as assessed by “omics” and functional analyses of cultured endometrial stromal cells derived from the biopsy. If so, then these findings would corroborate our transcriptomic and bioinformatics analyses of surplus CVS, which indicated impairment of decidualization actually begins before pregnancy [28] (Fig. 2). Potential downsides to this approach include: (i) preeclampsia *per se* in the index pregnancy may adversely affect endometrial maturation in subsequent menstrual cycles, (ii) the quality and extent of pre-decidualization in the conceptive cycle preceding the index preeclamptic pregnancy may not be the same in subsequent non-conceptive cycles, and (iii) preeclampsia recurrence is only ~ 20% [117]. With respect to the first of these potential pitfalls, a positive study outcome could be followed up in future investigations of banked, formalin-fixed paraffin embedded (FFPE) endometrial biopsies that were obtained *prior* to assisted reproductive cycles (“mock” cycles) starting with identification of obstetrical outcomes and

followed by gene expression analysis (technology for extracting sufficient quality RNA from FFPE tissues for gene expression analysis is emerging). However, this undertaking would be huge, and the approach involving endometrial biopsies after the index pregnancy of preeclampsia may indeed be more feasible as the first step. The second potential pitfall is difficult to address except by obtaining a positive outcome to the study. Regarding the last of the potential pitfalls, it is not inconceivable that the same impairment of pre-decidualization persists in subsequent menstrual cycles after the index preeclamptic pregnancy, but that compensatory maternal responses or compensation by extravillous trophoblasts mitigates preeclampsia recurrence. Alternatively, inadequate pre-decidualization may be a predisposing factor, and a “second hit” is needed to initiate the disease process. Although these potential pitfalls are all valid criticisms, they should not derail pursuit of obtaining endometrial biopsies, because the rewards, in the event of positive results, would be enormous. Moreover, specific molecular deficiencies or defects could conceivably be identified, and preventative or therapeutic countermeasures designed and tested to improve (pre)decidualization.

Finally, as depicted in Table 1, there may be circulating biomarkers of (pre)decidualization that could identify women who are at increased risk of developing preeclampsia. These biomarkers could be informed by the differential gene and protein expression in the endometrial biopsies as discussed above. Or, they could be informed by transcriptomic analyses available in the public domain of normal decidualization from early ectopic and intrauterine pregnancies [67]. Of course, all of these prospective approaches could be applied to investigating the role of aberrant (pre)decidualization in other adverse obstetrical outcomes that may arise from deficient placentation, too, such as preterm labor and normotensive intrauterine growth restriction.

Perspectives

The general premise presented in this treatise is that insufficient or defective maturation of endometrium before and during early pregnancy compromises immune cell number and/or phenotype leading to impaired trophoblast function, spiral artery remodeling, and consequently, the development of preeclampsia. Figure 4 depicts this concept in the context of the classic 2 or 3 step model for the pathogenesis of preeclampsia [12]. Although logistically challenging, we believe that this hypothesis is further testable (*vide supra*). For example, unveiling aberrant endometrial gene expression on endometrial biopsy of women in late secretory phase who were affected by severe preeclampsia in a prior pregnancy could inform targeted investigation and discovery of protein biomarkers in blood, urine or uterine feven before conception that eventually could constitute a diagnostic panel. Ultimately, designing interventions that improve endometrial maturation to facilitate normal placentation and reduce preeclampsia risk might be a logical therapeutic course of action [118].

The hypothesis that preeclampsia may arise from defective or insufficient endometrial maturation may not be particularly new [29], and might even be considered as self-evident or intuitive in light of the close proximity of decidual stromal, epithelial, and immune cells with trophoblast at the maternal-fetal interface. Nevertheless, prospective evidence (i.e.,

obtained during pregnancy months before disease onset or even before pregnancy), which is critically needed to lend credence to the concept has been missing until recently. Clearly, study of trophoblast and decidua from delivered placentas has revealed valuable insights into our understanding of preeclampsia pathogenesis, but perhaps not so much about etiology due to the retrospective timing of tissue acquisition. In this review, we bring together the new and emerging, prospective evidence supporting the concept that deficiency or defects in (pre)decidualization during the secretory phase and early pregnancy including dysregulation of uterine immune cell number and/or phenotype antedate preeclampsia at least in a subset of women who develop the disease. Indeed, the degree of impairment in (pre)decidualization likely impacts the severity of pregnancy outcome. Thus, implantation failure, miscarriage, preterm labor, intrauterine growth restriction and preeclampsia may arise from a spectrum of (pre)decidual insufficiency ranging from most to least severe. In support of this concept, we recently reported significant overlap of the transcriptomes in CVS from women who developed preeclampsia with secretory endometrium from women who experienced recurrent implantation failure or miscarriage [119].

Acknowledgments

The Global Pregnancy Collaboration is part of the Pre-eclampsia-Eclampsia Monitoring, Prevention & Treatment (PRE-EMPT) initiative funded by the University of British Columbia, a grantee of the Bill & Melinda Gates Foundation. We thank Robert N. Taylor MD, PhD for insightful comments and valuable collaboration. This work was supported in part by NIH PO1 HD065647.

References

1. Ilekis JV, Tsilou E, Fisher S, Abrahams VM, Soares MJ, Cross JC, Zamudio S, Illsley NP, Myatt L, Colvis C, Costantine MM, Haas DM, Sadovsky Y, Weiner C, Rytting E, Bidwell G. Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health Human Development. *Am J Obstet Gynecol.* 2016; 215(1 Suppl):S1–S46. [PubMed: 26972897]
2. Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. *Placenta.* 2009; 30(6):473–82. [PubMed: 19375795]
3. Pijnenborg R, Vercruysse L, Hanssens M, Brosens I. Endovascular trophoblast and preeclampsia: A reassessment. *Pregnancy Hypertens.* 2011; 1(1):66–71. [PubMed: 26104233]
4. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. *Obstet Gynecol Annu.* 1972; 1:177–91. [PubMed: 4669123]
5. Lyall F, Robson SC, Bulmer JN. Spiral artery remodeling and trophoblast invasion in preeclampsia and fetal growth restriction: relationship to clinical outcome. *Hypertension.* 2013; 62(6):1046–54. [PubMed: 24060885]
6. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. *Br J Obstet Gynaecol.* 1986; 93(10):1049–59. [PubMed: 3790464]
7. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. *Br J Obstet Gynaecol.* 1994; 101(8):669–74. [PubMed: 7947500]
8. Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. *J Clin Invest.* 1993; 91(3):950–60. [PubMed: 7680671]
9. Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. *Placenta.* 2006; 27(9–10):939–58. [PubMed: 16490251]

10. Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. *J Soc Gynecol Investig.* 2004; 11(6):342–52.
11. Redman CW, Sargent IL, Staff AC. IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia? *Placenta.* 2014; 35(Suppl):S20–5. [PubMed: 24477207]
12. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. *Science.* 2005; 308(5728):1592–4. [PubMed: 15947178]
13. Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. *Am J Obstet Gynecol.* 1996; 175(5):1365–70. [PubMed: 8942516]
14. Stubbs TM, Lazarchick J, Horger EO 3rd. Plasma fibronectin levels in preeclampsia: a possible biochemical marker for vascular endothelial damage. *Am J Obstet Gynecol.* 1984; 150(7):885–7. [PubMed: 6542311]
15. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. *Am J Obstet Gynecol.* 1989; 161(5):1200–4. [PubMed: 2589440]
16. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. *Am J Reprod Immunol.* 1997; 37(3):240–9. [PubMed: 9127646]
17. Bernstein IM, Meyer MC, Osol G, Ward K. Intolerance to volume expansion: a theorized mechanism for the development of preeclampsia. *Obstet Gynecol.* 1998; 92(2):306–8. [PubMed: 9699772]
18. Gyselaers W, Mullens W, Tomsin K, Mesens T, Peeters L. Role of dysfunctional maternal venous hemodynamics in the pathophysiology of pre-eclampsia: a review. *Ultrasound Obstet Gynecol.* 2011; 38(2):123–9. [PubMed: 21611996]
19. Khong Y, Brosens I. Defective deep placentation. *Best Pract Res Clin Obstet Gynaecol.* 2011; 25(3):301–11. [PubMed: 21109492]
20. Kelly R, Holzman C, Senagore P, Wang J, Tian Y, Rahbar MH, Chung H. Placental vascular pathology findings and pathways to preterm delivery. *Am J Epidemiol.* 2009; 170(2):148–58. [PubMed: 19509320]
21. Ward, K., Taylor, RN. Genetic Factors in the Etiology of Preeclampsia/Eclampsia. In: Taylor, RN, Roberts, JM, Cunningham, FG., Lindheimer, MD., editors. *Chesley's Hypertensive Disorders in Pregnancy.* Academic Press; San Diego: 2015. p. 57-80.
22. Damsky CH, Fisher SJ. Trophoblast pseudo-vasculogenesis: faking it with endothelial adhesion receptors. *Current opinion in cell biology.* 1998; 10(5):660–6. [PubMed: 9818178]
23. Fisher, SJ., McMaster, M., Roberts, JM. The Placental in Normal Pregnancy and Preeclampsia. In: Taylor, RN, Roberts, JM, Cunningham, FG., Lindheimer, MD., editors. *Chesley's Hypertensive Disorders in Pregnancy.* Academic Press; San Diego: 2015. p. 81-94.
24. Hunkapiller NM, Fisher SJ. Chapter 12. Placental remodeling of the uterine vasculature. *Methods Enzymol.* 2008; 445:281–302. [PubMed: 19022064]
25. Lim KH, Zhou Y, Janatpour M, McMaster M, Bass K, Chun SH, Fisher SJ. Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia. *Am J Pathol.* 1997; 151(6):1809–18. [PubMed: 9403732]
26. Brosens I, Pijnenborg R, Vercruysse L, Romero R. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. *Am J Obstet Gynecol.* 2011; 204(3):193–201. [PubMed: 21094932]
27. Zhou Y, Gormley MJ, Hunkapiller NM, Kapidzic M, Stolyarov Y, Feng V, Nishida M, Drake PM, Bianco K, Wang F, McMaster MT, Fisher SJ. Reversal of gene dysregulation in cultured cytotrophoblasts reveals possible causes of preeclampsia. *J Clin Invest.* 2013; 123(7):2862–72. [PubMed: 23934129]
28. Rabaglino MB, Post Uiterweer ED, Jeyabalan A, Hogge WA, Conrad KP. Bioinformatics approach reveals evidence for impaired endometrial maturation before and during early pregnancy in women who developed preeclampsia. *Hypertension.* 2015; 65(2):421–9. [PubMed: 25421975]
29. Brosens JJ, Pijnenborg R, Brosens IA. The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. *Am J Obstet Gynecol.* 2002; 187(5):1416–23. [PubMed: 12439541]
30. Wallace AE, Fraser R, Cartwright JE. Extravillous trophoblast and decidual natural killer cells: a remodelling partnership. *Hum Reprod Update.* 2012; 18(4):458–71. [PubMed: 22523109]

31. Benirschke, K., Kaufmann, P. Pathology of the Human Placenta. Fourth. Springer-Verlag; New York: 2000.
32. Craven CM, Morgan T, Ward K. Decidual spiral artery remodelling begins before cellular interaction with cytotrophoblasts. *Placenta*. 1998; 19(4):241–52. [PubMed: 9639319]
33. Burton GJ, Watson AL, Hempstock J, Skepper JN, Jauniaux E. Uterine glands provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy. *J Clin Endocrinol Metab*. 2002; 87(6):2954–9. [PubMed: 12050279]
34. Moffett A, Colucci F. Uterine NK cells: active regulators at the maternal-fetal interface. *J Clin Invest*. 2014; 124(5):1872–9. [PubMed: 24789879]
35. Cartwright JE, James-Allan L, Buckley RJ, Wallace AE. The role of decidual NK cells in pregnancies with impaired vascular remodelling. *J Reprod Immunol*. 2016
36. Xiong S, Sharkey AM, Kennedy PR, Gardner L, Farrell LE, Chazara O, Bauer J, Hiby SE, Colucci F, Moffett A. Maternal uterine NK cell-activating receptor KIR2DS1 enhances placentation. *J Clin Invest*. 2013; 123(10):4264–72. [PubMed: 24091323]
37. Ning F, Liu H, Lash GE. The Role of Decidual Macrophages During Normal and Pathological Pregnancy. *Am J Reprod Immunol*. 2016; 75(3):298–309. [PubMed: 26750089]
38. Nancy P, Erlebacher A. T cell behavior at the maternal-fetal interface. *Int J Dev Biol*. 2014; 58(2–4):189–98. [PubMed: 25023685]
39. Lockwood CJ, Yen CF, Basar M, Kayisli UA, Martel M, Buhimschi I, Buhimschi C, Huang SJ, Krikun G, Schatz F. Preeclampsia-related inflammatory cytokines regulate interleukin-6 expression in human decidual cells. *Am J Pathol*. 2008; 172(6):1571–9. [PubMed: 18467705]
40. Basar M, Yen CF, Buchwalder LF, Murk W, Huang SJ, Godlewski K, Kocamaz E, Arda O, Schatz F, Lockwood CJ, Kayisli UA. Preeclampsia-related increase of interleukin-11 expression in human decidual cells. *Reproduction*. 2010; 140(4):605–12. [PubMed: 20668109]
41. Hara N, Fujii T, Okai T, Taketani Y. Histochemical demonstration of interleukin-2 in decidua cells of patients with preeclampsia. *Am J Reprod Immunol*. 1995; 34(1):44–51. [PubMed: 7576130]
42. Wilczynski JR, Tchorzewski H, Glowacka E, Banasik M, Lewkowicz P, Szpakowski M, Zeman K, Wilczynski J. Cytokine secretion by decidual lymphocytes in transient hypertension of pregnancy and pre-eclampsia. *Mediators Inflamm*. 2002; 11(2):105–11. [PubMed: 12061422]
43. Huang SJ, Zenclussen AC, Chen CP, Basar M, Yang H, Arcuri F, Li M, Kocamaz E, Buchwalder L, Rahman M, Kayisli U, Schatz F, Toti P, Lockwood CJ. The implication of aberrant GM-CSF expression in decidual cells in the pathogenesis of preeclampsia. *Am J Pathol*. 2010; 177(5):2472–82. [PubMed: 20829438]
44. Rahimzadeh M, Norouzian M, Arabpour F, Naderi N. Regulatory T-cells and preeclampsia: an overview of literature. *Expert Rev Clin Immunol*. 2016; 12(2):209–27. [PubMed: 26580672]
45. Hsu P, Santner-Nanan B, Dahlstrom JE, Fadia M, Chandra A, Peek M, Nanan R. Altered decidual DC-SIGN+ antigen-presenting cells and impaired regulatory T-cell induction in preeclampsia. *Am J Pathol*. 2012; 181(6):2149–60. [PubMed: 23063509]
46. Faas MM, Spaans F, De Vos P. Monocytes and macrophages in pregnancy and pre-eclampsia. *Front Immunol*. 2014; 5:298. [PubMed: 25071761]
47. Schonkeren D, van der Hoorn ML, Khedoe P, Swings G, van Beelen E, Claas F, van Kooten C, de Heer E, Scherjon S. Differential distribution and phenotype of decidual macrophages in preeclamptic versus control pregnancies. *Am J Pathol*. 2011; 178(2):709–17. [PubMed: 21281803]
48. Prefumo F, Sebire NJ, Thilaganathan B. Decreased endovascular trophoblast invasion in first trimester pregnancies with high-resistance uterine artery Doppler indices. *Hum Reprod*. 2004; 19(1):206–9. [PubMed: 14688183]
49. Guzin K, Tomruk S, Tuncay YA, Naki M, Sezginsoy S, Zemheri E, Yucel N, Kanadikirik F. The relation of increased uterine artery blood flow resistance and impaired trophoblast invasion in pre-eclamptic pregnancies. *Arch Gynecol Obstet*. 2005; 272(4):283–8. [PubMed: 16007505]
50. Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW, Wapner RJ, Thorp JM Jr, Mercer BM, Grobman WA, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Tolosa G, Saade Y, Sorokin Y, Anderson, H GD. Eunice Kennedy Shriver National Institute of Child N. Human development Maternal-Fetal Medicine Units. The utility of uterine artery Doppler

- velocimetry in prediction of preeclampsia in a low-risk population. *Obstet Gynecol.* 2012; 120(4): 815–22. [PubMed: 22996099]
51. Conde-Agudelo, A., Romero, R., Roberts, JM. Roberts, Tests to predict preeclampsia. In: Taylor, RN. Roberts, JM. Cunningham, FG., Lindheimer, MD., editors. *Chesley's Hypertensive Disorders in Pregnancy*. Academic Press; San Diego, CA: 2015. p. 221-251.
 52. de Groot CJ, O'Brien TJ, Taylor RN. Biochemical evidence of impaired trophoblastic invasion of decidual stroma in women destined to have preeclampsia. *Am J Obstet Gynecol.* 1996; 175(1):24–9. [PubMed: 8694068]
 53. Hietala R, Pohja-Nylander P, Rutanen EM, Laatikainen T. Serum insulin-like growth factor binding protein-1 at 16 weeks and subsequent preeclampsia. *Obstet Gynecol.* 2000; 95(2):185–9. [PubMed: 10674577]
 54. Anim-Nyame N, Hills FA, Sooranna SR, Steer PJ, Johnson MR. A longitudinal study of maternal plasma insulin-like growth factor binding protein-1 concentrations during normal pregnancy and pregnancies complicated by pre-eclampsia. *Hum Reprod.* 2000; 15(10):2215–9. [PubMed: 11006202]
 55. Grobman WA, Kazer RR. Serum insulin insulin-like growth factor-I and insulin-like growth factor binding protein-1 in women who develop preeclampsia. *Obstet Gynecol.* 2001; 97(4):521–6. [PubMed: 11275021]
 56. Ning Y, Williams MA, Vadachkoria S, Muy-Rivera M, Frederick IO, Luthy DA. Maternal plasma concentrations of insulinlike growth factor-1 and insulinlike growth factor-binding protein-1 in early pregnancy and subsequent risk of preeclampsia. *Clin Biochem.* 2004; 37(11):968–73. [PubMed: 15498523]
 57. Vatten LJ, Nilsen TI, Juul A, Jeansson S, Jenum PA, Eskild A. Changes in circulating level of IGF-I and IGF-binding protein-1 from the first to second trimester as predictors of preeclampsia. *Eur J Endocrinol.* 2008; 158(1):101–5. [PubMed: 18166823]
 58. Founds SA, Conley YP, Lyons-Weiler JF, Jeyabalan A, Hogge WA, Conrad KP. Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. *Placenta.* 2009; 30(1):15–24. [PubMed: 19027158]
 59. Rajakumar A, Conrad KP. Expression ontogeny and regulation of hypoxia-inducible transcription factors in the human placenta. *Biol Reprod.* 2000; 63(2):559–69. [PubMed: 10906065]
 60. Rajakumar A, Brandon HM, Daftary A, Ness R, Conrad KP. Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. *Placenta.* 2004; 25(10):763–769. [PubMed: 15451190]
 61. Rajakumar A, Jeyabalan A, Markovic N, Ness R, Gilmour C, Conrad KP. Placental HIF-1 alpha HIF-2 alpha membrane and soluble VEGF receptor-1 proteins are not increased in normotensive pregnancies complicated by late-onset intrauterine growth restriction. *Am J Physiol.* 2007; 293(2):R766–74.
 62. Kohl P, Crampin EJ, Quinn TA, Noble D. Systems biology: an approach. *Clinical pharmacology and therapeutics.* 2010; 88(1):25–33. [PubMed: 20531468]
 63. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I, Gazit R, Yutkin V, Benharroch D, Porgador A, Keshet E, Yagel S, Mandelboim O. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. *Nat Med.* 2006; 12(9):1065–74. [PubMed: 16892062]
 64. Robson A, Harris LK, Innes BA, Lash GE, Aljunaidy MM, Aplin JD, Baker PN, Robson SC, Bulmer JN. Uterine natural killer cells initiate spiral artery remodeling in human pregnancy. *FASEB J.* 2012; 26(12):4876–85. [PubMed: 22919072]
 65. Smith SD, Dunk CE, Aplin JD, Harris LK, Jones RL. Evidence for immune cell involvement in decidual spiral arteriole remodeling in early human pregnancy. *Am J Pathol.* 2009; 174(5):1959–71. [PubMed: 19349361]
 66. Eastabrook G, Hu Y, von Dadelszen P. The role of decidual natural killer cells in normal placentation and in the pathogenesis of preeclampsia. *J Obstet Gynaecol Can.* 2008; 30(6):467–76. [PubMed: 18611298]

67. Duncan WC, Shaw JL, Burgess S, McDonald SE, Critchley HO, Horne AW. Ectopic pregnancy as a model to identify endometrial genes and signaling pathways important in decidualization and regulated by local trophoblast. *PLoS One*. 2011; 6(8):e23595. [PubMed: 21858178]
68. Koopman LA, Kopcow HD, Rybalov B, Boyson JE, Orange JS, Schatz F, Masch R, Lockwood CJ, Schachter AD, Park PJ, Strominger JL. Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. *J Exp Med*. 2003; 198(8):1201–12. [PubMed: 14568979]
69. Burney RO, Talbi S, Hamilton AE, Vo KC, Nyegaard M, Nezhat CR, Lessey BA, Giudice LC. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. *Endocrinology*. 2007; 148(8):3814–26. [PubMed: 17510236]
70. Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dosiou C, Le Shay N, Nezhat CN, Kempson R, Lessey BA, Nayak NR, Giudice LC. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. *Endocrinology*. 2006; 147(3):1097–121. [PubMed: 16306079]
71. Kopcow HD, Eriksson M, Mselle TF, Damrauer SM, Wira CR, Sentman CL, Strominger JL. Human decidual NK cells from gravid uteri and NK cells from cycling endometrium are distinct NK cell subsets. *Placenta*. 2010; 31(4):334–8. [PubMed: 20172608]
72. Gustafsson C, Mjosberg J, Matussek A, Geffers R, Matthiesen L, Berg G, Sharma S, Buer J, Ernerudh J. Gene expression profiling of human decidual macrophages: evidence for immunosuppressive phenotype. *PLoS One*. 2008; 3(4):e2078. [PubMed: 18446208]
73. Meng T, Chen H, Sun M, Wang H, Zhao G, Wang X. Identification of differential gene expression profiles in placentas from preeclamptic pregnancies versus normal pregnancies by DNA microarrays. *OMICS*. 2012; 16(6):301–11. [PubMed: 22702245]
74. Vaiman D, Calicchio R, Miralles F. Landscape of transcriptional deregulations in the preeclamptic placenta. *PLoS One*. 2013; 8(6):e65498. [PubMed: 23785430]
75. van Uitert M, Moerland PD, Enquobahrie DA, Laivuori H, van der Post JA, Ris-Stalpers C, Afink GB. Meta-Analysis of Placental Transcriptome Data Identifies a Novel Molecular Pathway Related to Preeclampsia. *PLoS One*. 2015; 10(7):e0132468. [PubMed: 26171964]
76. Winn VD, Gormley M, Fisher SJ. The Impact of Preeclampsia on Gene Expression at the Maternal-Fetal Interface. *Pregnancy Hypertens*. 2011; 1(1):100–8. [PubMed: 21743843]
77. Yong HE, Melton PE, Johnson MP, Freed KA, Kalionis B, Murthi P, Brennecke SP, Keogh RJ, Moses EK. Genome-wide transcriptome directed pathway analysis of maternal pre-eclampsia susceptibility genes. *PLoS One*. 2015; 10(5):e0128230. [PubMed: 26010865]
78. Loset M, Mundal SB, Johnson MP, Fenstad MH, Freed KA, Lian IA, Eide IP, Bjorge L, Blangero J, Moses EK, Austgulen R. A transcriptional profile of the decidua in preeclampsia. *Am J Obstet Gynecol*. 2011; 204(1):84, e1–27. [PubMed: 20934677]
79. Schulte MM, Tsai JH, Moley KH. Obesity and PCOS: the effect of metabolic derangements on endometrial receptivity at the time of implantation. *Reprod Sci*. 2015; 22(1):6–14. [PubMed: 25488942]
80. Bellver J, Martinez-Conejero JA, Labarta E, Alama P, Melo MA, Remohi J, Pellicer A, Horcajadas JA. Endometrial gene expression in the window of implantation is altered in obese women especially in association with polycystic ovary syndrome. *Fertil Steril*. 2011; 95(7):2335, 41, 2341, e1–8. [PubMed: 21481376]
81. Rhee JS, Saben JL, Mayer AL, Schulte MB, Asghar Z, Stephens C, Chi MM, Moley KH. Diet-induced obesity impairs endometrial stromal cell decidualization: a potential role for impaired autophagy. *Hum Reprod*. 2016; 31(6):1315–26. [PubMed: 27052498]
82. Piltonen TT. Polycystic ovary syndrome: Endometrial markers. *Best Pract Res Clin Obstet Gynaecol*. 2016; 37:66–79. [PubMed: 27156350]
83. Jakubowicz DJ, Essah PA, Seppala M, Jakubowicz S, Baillargeon JP, Koistinen R, Nestler JE. Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy. *J Clin Endocrinol Metab*. 2004; 89(2):833–9. [PubMed: 14764802]

84. Yu HF, Chen HS, Rao DP, Gong J. Association between polycystic ovary syndrome and the risk of pregnancy complications: A PRISMA-compliant systematic review and meta-analysis. *Medicine (Baltimore)*. 2016; 95(51):e4863. [PubMed: 28002314]
85. Sween LK, Althouse AD, Roberts JM. Early-pregnancy percent body fat in relation to preeclampsia risk in obese women. *Am J Obstet Gynecol*. 2015; 212(1):84, e1–7. [PubMed: 25088867]
86. Roberts JM, Bodnar LM, Patrick TE, Powers RW. The Role of Obesity in Preeclampsia. *Pregnancy Hypertens*. 2011; 1(1):6–16. [PubMed: 21532964]
87. Norambuena J, Pijnenborg R, Brosens I. Decidual changes in the endometrium and morphological adaptation of the associated supplying arteries in the normal and diabetic pseudopregnant rat. *Placenta*. 1984; 5(3):249–60. [PubMed: 6504859]
88. Garbis DR. Effects of diabetes on uterine condition decidualization, vascularization and corpus luteum function in the pseudopregnant rat. *Endocrinology*. 1988; 122(2):665–72. [PubMed: 3276500]
89. Weissgerber TL, Mudd LM. Preeclampsia and diabetes. *Curr Diab Rep*. 2015; 15(3):9. [PubMed: 25644816]
90. Glavind MT, Forman A, Arendt LH, Nielsen K, Henriksen TB. Endometriosis and pregnancy complications: a Danish cohort study. *Fertil Steril*. 2017; 107(1):160–166. [PubMed: 27743699]
91. Bulun SE. Endometriosis. *N Engl J Med*. 2009; 360(3):268–79. [PubMed: 19144942]
92. Yu J, Boicea A, Barrett KL, James CO, Bagchi IC, Bagchi MK, Nezhat C, Sidell N, Taylor RN. Reduced connexin 43 in eutopic endometrium and cultured endometrial stromal cells from subjects with endometriosis. *Mol Hum Reprod*. 2014; 20(3):260–70. [PubMed: 24270393]
93. Ormazabal P, Romero C, Quest AF, Vega M. Testosterone modulates the expression of molecules linked to insulin action and glucose uptake in endometrial cells. *Horm Metab Res*. 2013; 45(9): 640–5. [PubMed: 23700321]
94. Cermik D, Selam B, Taylor HS. Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2003; 88(1):238–43. [PubMed: 12519859]
95. Nuno-Ayala M, Guillen N, Arnal C, Lou-Bonafonte JM, de Martino A, Garcia-de-Jalon JA, Gascon S, Osaba L, Osada J, Navarro MA. Cystathionine beta-synthase deficiency causes infertility by impairing decidualization and gene expression networks in uterus implantation sites. *Physiol Genomics*. 2012; 44(14):702–16. [PubMed: 22617046]
96. Weiss G, Goldsmith LT, Taylor RN, Bellet D, Taylor HS. Inflammation in reproductive disorders. *Reprod Sci*. 2009; 16(2):216–29. [PubMed: 19208790]
97. Sakai N, Maruyama T, Sakurai R, Masuda H, Yamamoto Y, Shimizu A, Kishi I, Asada H, Yamagoe S, Yoshimura Y. Involvement of histone acetylation in ovarian steroid-induced decidualization of human endometrial stromal cells. *J Biol Chem*. 2003; 278(19):16675–82. [PubMed: 12609987]
98. Estella C, Herrer I, Atkinson SP, Quinonero A, Martinez S, Pellicer A, Simon C. Inhibition of histone deacetylase activity in human endometrial stromal cells promotes extracellular matrix remodelling and limits embryo invasion. *PLoS One*. 2012; 7(1):e30508. [PubMed: 22291969]
99. Nancy P, Tagliani E, Tay CS, Asp P, Levy DE, Erlebacher A. Chemokine gene silencing in decidual stromal cells limits T cell access to the maternal-fetal interface. *Science*. 2012; 336(6086):1317–21. [PubMed: 22679098]
100. Tabbaa ZM, Zheng Y, Daftary GS. KLF11 epigenetically regulates glycodelin-A a marker of endometrial biology via histone-modifying chromatin mechanisms. *Reprod Sci*. 2014; 21(3): 319–28. [PubMed: 24060634]
101. Tamura I, Sato S, Okada M, Tanabe M, Lee L, Maekawa R, Asada H, Yamagata Y, Tamura H, Sugino N. Importance of C/EBPbeta binding histone acetylation status in the promoter regions for induction of IGFBP-1 PRL and Mn-SOD by cAMP in human endometrial stromal cells. *Endocrinology*. 2014; 155(1):275–86. [PubMed: 24248464]
102. Kim SY, Romero R, Tarca AL, Bhatti G, Kim CJ, Lee J, Elsej A, Than NG, Chaiworapongsa T, Hassan SS, Kang GH, Kim JS. Methylation of fetal and maternal monocytes and macrophages at the feto-maternal interface. *Am J Reprod Immunol*. 2012; 68(1):8–27. [PubMed: 22385097]

103. Yamagata Y, Asada H, Tamura I, Lee L, Maekawa R, Taniguchi K, Taketani T, Matsuoka A, Tamura H, Sugino N. DNA methyltransferase expression in the human endometrium: down-regulation by progesterone and estrogen. *Hum Reprod*. 2009; 24(5):1126–32. [PubMed: 19202141]
104. Guerin LR, Moldenhauer LM, Prins JR, Bromfield JJ, Hayball JD, Robertson SA. Seminal fluid regulates accumulation of FOXP3+ regulatory T cells in the preimplantation mouse uterus through expanding the FOXP3+ cell pool and CCL19-mediated recruitment. *Biol Reprod*. 2011; 85(2):397–408. [PubMed: 21389340]
105. Robertson SA, Bromfield JJ, Tremellen KP. Seminal ‘priming’ for protection from pre-eclampsia—a unifying hypothesis. *J Reprod Immunol*. 2003; 59(2):253–65. [PubMed: 12896827]
106. Masoudian P, Nasr A, de Nanassy J, Fung-Kee-Fung K, Bainbridge SA, El Demellawy D. Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis. *Am J Obstet Gynecol*. 2016; 214(3):328–39. [PubMed: 26627731]
107. Opdahl S, Henningsen AA, Tiitinen A, Bergh C, Pinborg A, Romundstad PR, Wennerholm UB, Gissler M, Skjaerven R, Romundstad LB. Risk of hypertensive disorders in pregnancies following assisted reproductive technology: a cohort study from the CoNARTaS group. *Hum Reprod*. 2015; 30(7):1724–31. [PubMed: 25924655]
108. Chen ZJ, Shi Y, Sun Y, Zhang B, Liang X, Cao Y, Yang J, Liu J, Wei D, Weng N, Tian L, Hao C, Yang D, Zhou F, Shi J, Xu Y, Li J, Yan J, Qin Y, Zhao H, Zhang H, Legro RS. Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome. *N Engl J Med*. 2016; 375(6):523–33. [PubMed: 27509101]
109. Ishihara O, Araki R, Kuwahara A, Itakura A, Saito H, Adamson GD. Impact of frozen-thawed single-blastocyst transfer on maternal and neonatal outcome: an analysis of 277,042 single-embryo transfer cycles from 2008 to 2010 in Japan. *Fertil Steril*. 2014; 101(1):128–33. [PubMed: 24268706]
110. Lopez-Garcia P, Moreira D. Open Questions on the Origin of Eukaryotes. *Trends Ecol Evol*. 2015; 30(11):697–708. [PubMed: 26455774]
111. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. *Science*. 2009; 326(5960):1694–7. [PubMed: 19892944]
112. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. *Nat Rev Genet*. 2012; 13(4):260–70. [PubMed: 22411464]
113. Mitchell CM, Haick A, Nkwopara E, Garcia R, Rendi M, Agnew K, Fredricks DN, Eschenbach D. Colonization of the upper genital tract by vaginal bacterial species in nonpregnant women. *Am J Obstet Gynecol*. 2015; 212(5):611, e1–9. [PubMed: 25524398]
114. Verstraelen H, Vilchez-Vargas R, Desimpel F, Jauregui R, Vankeirsbilck N, Weyers S, Verhelst R, De Sutter P, Pieper DH, Van De Wiele T. Characterisation of the human uterine microbiome in non-pregnant women through deep sequencing of the V1–2 region of the 16S rRNA gene. *PeerJ*. 2016; 4:pe1602.
115. Moreno I, Codoner FM, Vilella F, Valbuena D, Martinez-Blanch JF, Jimenez-Almazan J, Alonso R, Alama P, Remohi J, Pellicer A, Ramon D, Simon C. Evidence that the endometrial microbiota has an effect on implantation success or failure. *Am J Obstet Gynecol*. 2016; 215(6):684–703. [PubMed: 27717732]
116. Woo V, Alenghat T. Host-microbiota interactions: epigenomic regulation. *Curr Opin Immunol*. 2017; 44:52–60. [PubMed: 28103497]
117. van Oostwaard MF, Langenveld J, Schuit E, Papatsonis DN, Brown MA, Byaruhanga RN, Bhattacharya S, Campbell DM, Chappell LC, Chiaffarino F, Crippa I, Facchinetti F, Ferrazzani S, Ferrazzi E, Figueiro-Filho EA, Gaugler-Senden IP, Haavaldsen C, Lykke JA, Mbah AK, Oliveira VM, Poston L, Redman CW, Salim R, Thilaganathan B, Vergani P, Zhang J, Steegers EA, Mol BW, Ganzevoort W. Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. *Am J Obstet Gynecol*. 2015; 212(5):624, e1–17. [PubMed: 25582098]
118. Conrad KP. G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention. *Hum Reprod Update*. 2016; 22(5):647–64. [PubMed: 27385360]

119. Rabaglino MB, Post Uiterweer ED, Conrad KP. Evidence for partial overlap of molecular etiology between preeclampsia and decidualization disorders. *Reproductive Sci.* 2017; 24:91A.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1.

Circulating IGFBP-1 concentrations in normal pregnancy and preeclampsia. **(A)** Serial measurements of IGFBP-1 were performed throughout pregnancy. IGFBP-1 was significantly reduced in preeclampsia compared to normal pregnancy at 16, 20, and 24 weeks of gestation ($p=0.006$, $p=0.001$, and $p=0.04$, respectively). IGFBP-1 was significantly elevated in preeclampsia at 36 weeks of gestation ($p=0.04$). **(B)** Scatterplot of data from 16 gestational weeks shows good separation of data points between the 2 cohorts. Anim-Nyame et al., 2000 with permission.

Figure 2.

Average expression levels (log base 2) of differentially expressed genes (DEG) in samples obtained from endometrium at different stages of endometrial maturation and from chorionic villous samples (CVS). PE: preeclampsia; NP-normal pregnancy. PrE, ESE, MSE, LSE: proliferative and early, middle and late secretory endometrium, respectively; IntDEC, ConfDEC and nonDEC: intermediate, confluent and non-decidualized endometrium determined histologically. Significantly different ($P < 0.05$) from: a, PrE; b, ESE; c, MSE; d, LSE; e, intDEC-EP; f, intDEC-IUP; g, nonDEC; * $P < 0.0001$ vs nonpregnant (NP)-CVS. Rabaglino et al., 2015 with permission.

Endometrial antecedents of preeclampsia: A pathway to disease?

Figure 3.

Aberrant decidualization in the late secretory phase and during early pregnancy may play a role in the development of preeclampsia for some women. See text for details.

Endometrial antecedents of preeclampsia: A pathway to disease?

Figure 4.

Composite model of preeclampsia that includes the concept of dysregulated decidual and immune cell function in the genesis of impaired placentation (steps 1–3) prior to the traditional 2 or 3 stage model of disease pathogenesis (steps 4–6).

Table 1

Lower circulating concentrations of insulin growth factor binding protein-1 (IGFBP-1) in early pregnancy is associated with the development of preeclampsia.

Ref.	No. Subjects	Average Gestational Age (weeks)	Circulating IGFBP-1 Concentration (ng/ml)	P value
de Groot, 1996	20NP/20PE	19	79±15 vs 36±6 (mean±SEM)	=0.02
Hietala, 2000	794NP/34PE	16	103±62 vs 73±43 (mean±SD)	<0.01
Anim-Nyame, 2000	12NP/10PE	16, 20, 24, 28, 32, 36	See Figure 1	
Grobman, 2001	24NP/12PE	22	130±66 vs 84±41 (mean±SD)	<0.05
Ning, 2004	477NP/53PE	13	53[32–83] vs 39[19–58] Median[IQR]	<0.01
Vatten, 2008	Normal Pregnancy 274 1 st Tri 286 2 nd Tri 95 Overlapping Preeclampsia (>37 wk) 143 1 st Tri. 128 2 nd Tri 47 Overlapping Preeclampsia (<37 wk) 107 1 st Tri. 108 2 nd Tri. 42 Overlapping	 9 22 9 22 9 22	Reduced IGFBP-1 during 1 st and 2 nd Tri. in the lowest quartile is related to higher risk of <u>term PE</u> : OR 4.0 (1.9–8.4) and 2.3 (1.2–4.4), respectively; but not <u>preterm PE</u> : OR 1.5 (0.7–3.3) and 1.7 (0.9–3.1), respectively. NB. Absolute values for IGFBP-1 not reported.	

PE, preeclampsia; NP, normal pregnancy. Average gestational age (weeks) when blood was obtained for analysis of IGFBP-1. Many of the same subjects were studied both in the 1st and 2nd trimesters (overlapping). See References for complete citations.

Table 2

A. Bioinformatics analysis reveal little overlap of differentially expressed genes changing in the same direction in chorionic villous samples from women who later developed preeclampsia and differentially expressed genes in villous or isolated villous cytotrophoblast of delivered placentas from women who experienced preeclampsia.				
Publication	No. DEG (CVS)	No. DEG(Delivered Placenta)	No. Overlapping DEG (In Same Direction)	Comments
Zhou Y et al. JCI 123:2862–2672, 2013	396	907	3 upregulated 5 downregulated	<i>Isolated Cytotrophoblast.</i> 5 subjects with severe PE and 5 with preterm labor without signs of infection. Data downloaded from GEO #GSE40182, and reanalyzed. Only freshly isolated CTB samples were included in the analysis.
Meng T et al. OMICS 16: 301, 2012	396	860	3 upregulated 5 downregulated	<i>Villous.</i> 6 subjects each for preeclampsia and normal pregnancy. Data abstracted from Supplementary Material 1.
Vaiman D et al. PLOS One e65498: 1–14, 2013	396	98	0	<i>All villous except 1 basal plate decidua sample.</i> Meta-analysis of 6 datasets, which included a total of 79 PE and 96 NP subjects (Supplementary Tables 1 and 2).
Van Uitert M et al. PLOS One DOI: 10.1371/journal.pone.0132468: 1–15, 2015	396	388	1 upregulated 1 downregulated	<i>All villous except 1 basal plate, 1 villous + basal plate, and 1 unspecified sample.</i> Meta-analysis of 11 datasets, which included a total of 116 PE and 139 NP subjects (Supplementary Table 1).

B. Bioinformatics analysis reveals little overlap of differentially expressed genes changing in the same direction in chorionic villous samples from women who later developed preeclampsia and differentially expressed genes in decidua basalis of delivered placentas from women who experienced preeclampsia.				
Publication	No DEG (CVS)	No. DEG (Delivered Placenta)	No. Overlapping DEG (In Same Direction)	Comments
Winn VD et al. Pregnancy Hypertens. 1:100–108, 2011	396	116	0 upregulated 3 downregulated (p=0.01)	<i>Basal plate decidua.</i> 12 women with severe preeclampsia and 11 with preterm labor without signs of infection. Data from Supplemental Figure S1.
Yong HEJ et al. Plos One 2015. 10(5): p. e0128230	396	407	2 upregulated 1 downregulated	<i>Basal plate decidua.</i> 60 women with PE and 65 with normal pregnancies (Supplemental Table 4).
Loiset M et al. Am J Obstet Gynecol. 204:84.e1–e27, 2011	396	454	0	<i>Basal plate decidua.</i> 43 women with preeclampsia and 59 with normal pregnancies (Table 2).

PE, preeclampsia; NP, normal pregnancy; CVS, chorionic villous samples; DEG, differentially expressed genes between women who experienced preeclampsia vs normal pregnancy. No. DEG (CVS) from Rabaglino MB et al. Hypertension 65:421–9, 2015. See References for complete citations.